RESEARCH TRIANGLE PARK, N.C., Oct. 11, 2012 /PRNewswire/ -- Marken announced today that it was recently inspected by US Customs and Border Protection (CBP) and designated as a C-TPAT (Customs-Trade Partnership Against Terrorism) certified company.
US Customs and Border Protection (CBP) Supply Chain Security Specialists examined Marken's supply chain security program across their global network and confirmed that Marken is in compliance with the C-TPAT Program requirements. As a C-TPAT member subject to inspections every 4 years, Marken has continued to maintain compliance since first becoming a member in 2008. Marken was assessed across many areas including facility security, access controls, IT security, training, and threat awareness along with several other elements of their security program.
The safety and security of facilities and intellectual property & data are of paramount importance to Marken. A proven history of compliance and continued prioritization and focus on appropriate and effective security measures ensures that Marken operates and often surpasses all national requirements and best practices expected within the international aviation environment.
Robert Tungatt, Vice President CORTEC responsible for Marken's Global Security Program, said, "This certification validates the security of our global supply chain. We remain vigilant to new threats & risks as our service expands and develops. Utilizing new technologies, recognized best practices and compliance with national and international laws and regulations, we assure that our business partners continue to benefit from Marken's C-TPAT membership and other Trusted Trader and Security programs."
For more information on Marken's C-TPAT compliance, please contact CORTEC via CORTEC@marken.com.
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.